ondansetron has been researched along with Neuralgia in 8 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Neuralgia: Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The involvement of opioid receptor activation in the antinociceptive effect of either fluvoxamine, a selective serotonin reuptake inhibitor, or serotonin (5-HT) on thermal hyperalgesia and mechanical allodynia in a model of neuropathic pain in mice induced by sciatic nerve ligation was examined." | 3.73 | Possible involvement of opioidergic systems in the antinociceptive effect of the selective serotonin reuptake inhibitors in sciatic nerve-injured mice. ( Kamei, J; Nozaki, C, 2006) |
| " Population pharmacokinetic (PK) modelling was implemented to describe the average and individual plasma and CSF profiles of ondansetron." | 1.62 | Plasma and cerebrospinal fluid pharmacokinetics of ondansetron in humans. ( Back, H; Blood, J; Chiang, MD; Frey, K; Haroutounian, S; Kagan, L; Kharasch, ED; Lee, C; Sawyer, C; Tallchief, D, 2021) |
| " Mechanistic pharmacokinetic model that included two systemic disposition and three CNS compartments (with intercompartmental exchange) was developed." | 1.56 | Pharmacokinetic Modeling of the Impact of P-glycoprotein on Ondansetron Disposition in the Central Nervous System. ( Back, HM; Chiang, M; Girgis, S; Guo, T; Haroutounian, S; Kagan, L; Lee, JB; Oh, S; Park, C, 2020) |
| "Mechanisms underlying the chronicity of neuropathic pain are not well understood." | 1.39 | Descending facilitation maintains long-term spontaneous neuropathic pain. ( De Felice, M; Guo, W; King, T; Ossipov, MH; Porreca, F; Wang, R, 2013) |
| "Interestingly, tactile allodynia and thermal hyperalgesia in both models can be blocked similarly by intrathecal, but not systemic, injection of ondansetron." | 1.39 | Spinal 5-HT3 receptors facilitate behavioural hypersensitivity induced by elevated calcium channel alpha-2-delta-1 protein. ( Chang, EY; Chen, X; Li, CY; Luo, ZD; Sandhu, A, 2013) |
| "Chronic neuropathic pain is a frequent, serious outcome of spinal cord injury (SCI) that is highly refractory to treatment." | 1.35 | Blockade of the 5-HT3 receptor for days causes sustained relief from mechanical allodynia following spinal cord injury. ( Chen, Y; Oatway, MA; Weaver, LC, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chiang, MD | 1 |
| Frey, K | 1 |
| Lee, C | 1 |
| Kharasch, ED | 1 |
| Tallchief, D | 1 |
| Sawyer, C | 1 |
| Blood, J | 1 |
| Back, H | 1 |
| Kagan, L | 2 |
| Haroutounian, S | 2 |
| Chiang, M | 1 |
| Back, HM | 1 |
| Lee, JB | 1 |
| Oh, S | 1 |
| Guo, T | 1 |
| Girgis, S | 1 |
| Park, C | 1 |
| Patel, R | 1 |
| Dickenson, AH | 1 |
| Wang, R | 1 |
| King, T | 1 |
| De Felice, M | 1 |
| Guo, W | 1 |
| Ossipov, MH | 1 |
| Porreca, F | 1 |
| Sagalajev, B | 1 |
| Bourbia, N | 1 |
| Beloushko, E | 1 |
| Wei, H | 1 |
| Pertovaara, A | 1 |
| Chen, Y | 1 |
| Oatway, MA | 1 |
| Weaver, LC | 1 |
| Chang, EY | 1 |
| Chen, X | 1 |
| Sandhu, A | 1 |
| Li, CY | 1 |
| Luo, ZD | 1 |
| Nozaki, C | 1 |
| Kamei, J | 1 |
8 other studies available for ondansetron and Neuralgia
| Article | Year |
|---|---|
Plasma and cerebrospinal fluid pharmacokinetics of ondansetron in humans.
Topics: Administration, Intravenous; Humans; Infusions, Intravenous; Neuralgia; Ondansetron; Plasma | 2021 |
Pharmacokinetic Modeling of the Impact of P-glycoprotein on Ondansetron Disposition in the Central Nervous System.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain; Central Nervous System; Fem | 2020 |
Modality selective roles of pro-nociceptive spinal 5-HT
Topics: Animals; Disease Models, Animal; Ketanserin; Male; Membrane Potentials; Neural Pathways; Neuralgia; | 2018 |
Descending facilitation maintains long-term spontaneous neuropathic pain.
Topics: Afferent Pathways; Anesthetics, Local; Animals; Benzodiazepines; Conditioning, Operant; Disease Mode | 2013 |
Bidirectional amygdaloid control of neuropathic hypersensitivity mediated by descending serotonergic pathways acting on spinal 5-HT3 and 5-HT1A receptors.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amygdala; Animals; Dizocilpine Maleate; Glutamic Acid; Male; | 2015 |
Blockade of the 5-HT3 receptor for days causes sustained relief from mechanical allodynia following spinal cord injury.
Topics: Animals; Infusions, Intravenous; Injections, Spinal; Male; Neuralgia; Ondansetron; Rats; Rats, Wista | 2009 |
Spinal 5-HT3 receptors facilitate behavioural hypersensitivity induced by elevated calcium channel alpha-2-delta-1 protein.
Topics: Animals; Calcium Channels; Hyperalgesia; Injections, Intraperitoneal; Injections, Spinal; Male; Mice | 2013 |
Possible involvement of opioidergic systems in the antinociceptive effect of the selective serotonin reuptake inhibitors in sciatic nerve-injured mice.
Topics: Analgesics; Animals; Dose-Response Relationship, Drug; Fluvoxamine; Hyperalgesia; Injections, Spinal | 2006 |